Notizie e Video - FIBROCELL SCIENCE INC.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Fibrocell Science, Inc. PR Newswire NEW YORK, Oct. 25, 2019 NEW YORK , Oct. 25, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Fibrocell Science, Inc. ("FCSC" or the "Company") (NASDAQ: FCSC) in connection with the proposed acquisition of the Company by Castle Creek Pharmaceuticals, Inc. Under the terms of the acquisition agreement, FCSC shareholders will receive $3.00...

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Fibrocell Science, Inc. (NASDAQ: FCSC) on Behalf of Fibrocell Shareholders and Encourages Fibrocell Investors to Contact the Firm PR Newswire NEW YORK, Sept. 17, 2019 NEW YORK , Sept. 17, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Fibrocell Science, Inc. (NASDAQ: FCSC) on behalf of Fibrocell shareholders concerning the proposed merger with Castle Creek...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Fibrocell Science, Inc. (NasdaqGS: FCSC) to Castle Creek Pharmaceutical Holdings, Inc. Under the terms of the proposed transaction, shareholders of Fibrocell will receive only $3.00 in cash for each share of Fibrocell that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or...

...

NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Fibrocell Science Inc (NASDAQ:FCSC), Sears Hometown and Outlet Stores, Inc. (NASDAQ:SHOS), Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), Sigma Labs, Inc. (NASDAQ:SGLB), Highpower International Inc (NASDAQ:HPJ), and Nicholas Financial, Inc. (NASDAQ:NICK), including updated...

...

...

...

NEW YORK, NY / ACCESSWIRE / November 13, 2017 / Fibrocell Science, Inc. (NASDAQ: FCSC ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 13, 2017 at 8:30 AM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/24096 . To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor...

NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Fibrocell Science, Inc. (NASDAQ: FCSC ) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 9, 2017 at 8:30 AM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/24096 . Replay Information The replay will be available online at https://www.investornetwork.com/company/24096 . About Investor Network Investor Network (IN) is a new financial content community, serving...

NEW YORK, NY / ACCESSWIRE / May 10, 2017 / Fibrocell Science, Inc. (NASDAQ: FCSC ) will be discussing their earnings results in their Q1 Earnings Call to be held May 10, 2017 at 8:30 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/24096 . Replay Information The replay will be available online at https://www.investornetwork.com/company/24096 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

EXTON, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U. S. Food and Drug Administration (FDA) has granted Fast Track designation to FCX-007, the Company’s clinical-stage candidate for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)—a rare, devastating genetic skin disease for which no...

John Maslowski Succeeds David Pernock as Chief Executive Officer; Douglas Swirsky Appointed Chairman of the Board of Directors EXTON, Pa., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today announced that John Maslowski has been appointed Chief Executive Officer (CEO) and Douglas Swirsky has been appointed Chairman of the Company’s Board of Directors, succeeding David Pernock effective immediately. In addition, Mr. Maslowski has been appointed to the Company’s...

EXTON, Pa., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today announced the appointment of Alfred T. Lane, MD, as Chief Medical Advisor of Fibrocell. A board certified dermatologist and pediatrician, Dr. Lane is a Professor of Dermatology and Pediatrics (Emeritus) at Stanford University School of Medicine and the former Chair of the Department of Dermatology where he led a research team focused on developing gene therapy for Epidermolysis Bullosa (EB) and other...

EXTON, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today reported financial results for the third quarter ended September 30, 2016 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT. “Fibrocell is focused on advancing our innovative gene therapy candidates that use genetically-modified autologous fibroblast cells to target the underlying cause of debilitating skin and connective tissue diseases and have...

EXTON, Pa., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) will report financial results for the third quarter ended September 30, 2016 and recent operational highlights on Thursday, November 3, 2016, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks. To...

ARLINGTON, VA / ACCESSWIRE / October 11, 2016 / Fibrocell Science, Inc. (NASDAQ:FCSC) will be presenting at this year's The MicroCap Conference on October 24-25 in Philadelphia at the Hotel Monaco, along with 60 other companies in the microcap universe. The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert...

EXTON, Pa., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC) today announced that John Maslowski, Senior Vice President, Scientific Affairs of Fibrocell, will present at 9:15 am PDT on Thursday, October 6 at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 5-7 in La Jolla, California. A live webcast of Fibrocell’s presentation will be available under the investor relations section of the company’s website at...